
Opinion|Videos|May 19, 2025
Strengths and Weaknesses of Imaging Modalities in ccRCC
Explore the strengths and weaknesses of imaging modalities like CT, MRI, and ultrasound in diagnosing ccRCC and enhancing patient care.
Advertisement
Episodes in this series

Strengths and Limitations of Different Imaging Modalities
Main Discussion Topics:
- CT scans remain the most common initial imaging modality for renal mass detection.
- MRI offers additional sequencing capabilities for better tumor characterization.
- Ultrasound primarily helps determine whether masses are solid or cystic.
- Nuclear imaging (prostate-specific membrane antigen [PSMA] scans) shows potential but has demonstrated limited accuracy.
Key Points for Physicians:
- CT is widely available and familiar to most clinicians.
- MRI provides superior soft tissue characterization and additional sequences.
- Ultrasound is useful for determining whether a mass is solid vs cystic.
- Nuclear medicine studies such as PSMA scans have not demonstrated sufficient accuracy.
Notable Insights:
Each imaging modality has specific advantages, but many patients arrive with inadequate initial imaging, requiring additional studies for proper characterization.
Clinical Significance:
Understanding the strengths and limitations of each imaging modality allows clinicians to select appropriate studies for comprehensive renal mass evaluation.
Advertisement
Related to this article

Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.

A national study found that use of MRI before prostate biopsy increased in US hospitals from 2017 through the first half of 2026.

The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.

The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.

The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.

Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.
Advertisement
Advertisement
Trending on Urology Times
1
Evidence for Combining Prostatic Urethral Lift With Radiotherapy
2
FDA grants breakthrough device designation to urine ID/AST panel
3
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
4
Use of prebiopsy prostate MRI increasing across US hospitals, study finds
5

